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Effects of Theophylline on Chronic
Inflammatory Lung Injury Induced
by LPS Exposure in Guinea Pigs
Yoshio Kaneko1, Kazumi Takashima1, Naomi Suzuki1 and Kenjiro Yamana1
ABSTRACT
Background: Pathogenesis of COPD is, at least in part, attributable to the chronic accumulation of neutro-
phils in the airways, and morphological changes such as hyperplasia of goblet cells in the airways are often ob-
served in this disease. These structural changes were induced in guinea pigs by repetitive inhalations of LPS,
and the effects of theophylline and dexamethasone were examined.
Methods: Male Hartley Guinea pigs weighing about 300 g were exposed to a nebulized solution of LPS (30
μgmL) for 1 hour. Exposure to LPS was performed 15 times at 48-hour intervals. Histological analysis was
performed, and infiltration of leukocytes in BALF, airway hyperreactivity and hydroxyproline content of the lung
were measured 24 or 48 hours after the final exposure of LPS. Drugs were administered every day until 30 min-
utes before the final exposure.
Results: Repetitive exposure to LPS induced an influx of inflammatory cells into the BALF. Histological
changes such as accumulation of inflammatory cells in the lung parenchyma, enlargement of alveoli, swelling
of the alveolar walls and goblet cell hyperplasia in the airways were observed. Airway hyperreactivity and in-
creased lung hydroxyproline content were also found in this model of chronic inflammatory lung injury. Some of
these changes induced by repetitive LPS exposure were improved by treatment with theophylline or dex-
amethasone.
Conclusions: Theophylline improved airway injury as well as airway hyperreactivity induced by repetitive ex-
posure of the guinea pigs to LPS. These results suggest that theophylline treatment has ameliorative effects on
airway disease with chronic inflammation.
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INTRODUCTION
Chronic airway diseases including chronic obstruc-
tive pulmonary disease (COPD) are becoming impor-
tant therapeutic targets, as mortality from these dis-
eases rises. Many methods have been developed for
animal studies of chronic airway diseases such as al-
lergic inflammation, bronchitis, airway remodeling,
emphysema or fibrosis that were induced by antigen
or ovalbumin (OVA),1-3 lipopolysaccharide (LPS),4-10
cigarette smoke,11,12 diesel exhaust,13 bleomycin,14,15
elastase16,17 or silica.18
LPS is an endotoxin from gram-negative bacteria
that induces circulatory shock, coagulopathy and
multiorgan dysfunction as well as a strong response
in the immune system. Administration of LPS causes
influx of inflammatory cells such as macrophages,
neutrophils and lymphocytes, with increasing release
of pro-inflammatory cytokines such as tumor necrosis
factor (TNF)-α, interleukin (IL)-1β and interferon-
γ.19,20 These inflammatory reactions induced by a sin-
gle dose of LPS to the airway via inhalation or intra-
tracheal administration have been used in animal
models of acute lung injury (ALI)21,22 or acute respi-
ratory distress syndrome (ARDS).23,24 On the other
hand, repetitive exposure of LPS induces prolonged
inflammation characterized by neutrophil accumula-
tion in the airway of mice and guinea pigs.4-10 During
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chronic inflammation by repeated LPS exposure,
some pathological changes similar to those observed
in COPD patients have been reported. For example,
goblet cell hyperplasia in the airways25,26 and chronic
neutrophilia in the bronchi, bronchioles and alveoli27
showed some of the pathological features of chronic
bronchitis, and swelling of the alveolar walls and al-
veolar enlargement28 represent aspects of emphy-
sema.
Theophylline, a nonselective phosphodiesterase
(PDE) inhibitor, has been used in the treatment of
respiratory diseases such as bronchial asthma for
many years. The beneficial effects of theophylline
have usually been attributed to both bronchodilatory
and anti-inflammatory activities based on their activ-
ity in the inhibition of PDE enzymes, especially PDE
isoenzyme type IV. Furthermore, theophylline has
been reported to show many mechanisms in inflam-
matory reactions, for example, adenosine receptor an-
tagonism, increased IL-10 release, mediator inhibi-
tion, inhibition of inflammatory cytokines, and in-
creased histone deacetylase activity (HDAC).29-31
These actions of theophylline may be efficacious for
the treatment of chronic airway disease. In interna-
tional guidelines for the treatment of COPD, theo-
phylline has been categorized as a bronchodilator to-
gether with inhaled anticholinergics and beta-
agonists.32 However, anti-inflammatory effect theo-
phylline may be reflected on its clinical effects in ad-
dition to bronchodilatory effects.
Theophylline has been reported to have a strong
ameliorative effect on chronic airway inflammation in
animal models, but little is known about its effects on
histological changes after prolonged inflammation. In
the present study, the lung injury characterized by
chronic neutrophilic inflammation was induced by re-
petitive exposure of the guinea pigs to LPS, and the
effects of theophylline on inflammation and histologi-
cal changes in the airway were examined.
METHODS
ANIMALS
Male Hartley Guinea pigs weighing about 300 g were
purchased from Charles River Japan (Yokohama, Ja-
pan). The animals were housed in an air-conditioned
room (23 ± 2℃, 50 ± 10% humidity) lit from 8:00―
20:00, and were allowed food and water ad libitum
throughout the experiments. The experiments were
undertaken according to the “Guidelines for the care
and use of experimental animals” provided by the
Japanese Association for Laboratory Animal Science
(1987).
DRUGS AND MATERIALS
LPS (Escherichia coli, serotype O55: B5) and dex-
amethasone were purchased from Sigma-Aldrich Co.
(St. Louis, MO, USA). Theophylline was purchased
from Wako Pure Chemical Industries, Ltd., (Osaka,
Japan). LPS was dissolved in phosphate-buffered sa-
line (PBS). Dexamethasone and theophylline were
suspended in a 0.5% solution of carboxymethylcellu-
lose sodium (Wako Pure Chemical Industries, Ltd.).
Pentobarbital sodium was purchased from Dainippon
Sumitomo Pharma Co., Ltd. Trypan Blue and Diff
Quick were purchased from GIBCO-BRL (Gaithers-
burg, MD, USA) and International Reagent Corp.
(Kobe, Japan). Acetyl-β-methylcholine bromide (me-
thacholine) and hydroxyproline were purchased from
Sigma-Aldrich.
EXPERIMENTAL PROTOCOL FOR LPS EXPO-
SURES
Guinea pigs were exposed to an aerosolized solution
of LPS (30 μgmL dissolved in physiological saline,
60 mL ) for 1 hour. Exposure was performed 15 times
at 48-hour intervals using an ultrasonic nebulizer
(NE-U12, Omron, Kyoto, Japan). Twenty-four hours
after the final exposure, bronchoalveolar lavage fluid
(BALF) was collected and the lungs were removed
for histological analysis. In other groups of guinea
pigs methacholine-induced airway hyper-reactivity
(AHR) was measured 48 hours after the final expo-
sure, and their lungs were removed to measure the
hydroxyproline content. Test drugs and vehicle were
administered every day during the course of the ex-
periment until 30 minutes before the final exposure to
LPS. Animals in the sham-exposure group were not
exposed to LPS. These experimental procedures are
shown in Figure 1.
LEUKOCYTE COUNT IN BALF
The leukocytes in BALF were counted at 4, 24 and 47
hours after the first exposure and at 24 hours after
the 5th, 10th and 15th exposures to LPS. Guinea pigs
were deeply anesthetized with pentobarbital sodium
and sacrificed by exsanguination. In the time course
study of cell accumulation (Fig. 2A), five times, 5 mL
of physiological saline was injected into, and fluid was
collected from, the whole lung via a tracheal cannula
(total 25 mL). In another study of cell accumulation
(Fig. 3A), 2.5 mL of physiological saline was injected
five times into, and fluid was collected from, the left
lobe of the lung via a tracheal cannula (total 12.5 mL),
while the right bronchus was ligatured. BALF was
centrifuged at 500 g, 4℃ for 10 minutes, and the pel-
let was resuspended in 5 mL of PBS after brief hemo-
lytic treatment with hypotonic solution, and the cells
were washed twice with 5 mL of PBS. The total and
differential cell numbers were counted by light mi-
croscopy after staining with trypan blue and Diff
Quick, respectively.
HISTOLOGICAL ANALYSIS
Immediately after BAL, the lobes of the right lung
were removed, rinsed with PBS, and fixed by 2.5 mL
of 10% phosphate-buffered formalin (pH 7.4) via tra-
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Fig. 1 Schedule of the study. LPS exposure was performed for 60 min
utes every 2 days for a maximum of 15 times. BALF was colected at 4 
hours, 24 hours and 47 hours after the first exposure to LPS, and 24 hours 
after the 5th, 10th and 15th exposure to LPS. Lung sampling for hydroxypro
line assay was caried out at 48 hours after the 1st, 5th, 10th and 15th expo
sure to LPS. Lungs for histological analysis were sampled at 24 hours, and 
AHR was measured at 48 hours after the final exposure to LPS. Test drugs 
were administered every day, usualy 30 minutes before exposure on days 
of LPS chalenge.
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Fig. 2 Time course of the changes of inflammatory cel accumulation in the BALF and lung hydroxypro
line content induced by repetitive exposure to LPS. LPS was inhaled at the 1st, 5th, 10th and 15th exposure. 
(A) The number of total cels and neutrophils in the BALF was counted at 4, 24 and 47 hours after the 1st 
exposure and at 24 hours after the 5th, 10th and 15th exposure to LPS. (B) The lung hydroxyproline content 
was measured at 24 hours after the 1st, 5th, 10th and 15th exposure to LPS. Each column represents 
means ± S.E.M. (n＝4―6). #: p＜0.05, ##: p＜0.01 v.s. sham group.
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cheal cannula attached to the right bronchus. The
lung was preserved in 10% phosphate-buffered forma-
lin for one more day. After fixation, portions of the
center of the middle lobe were removed so that the
large bronchi appeared at the surface, and embedded
in paraffin. Sections 10 μm thick were cut, deparaf-
finized, and stained with hematoxylin and eosin (H&
E), Alcian blue-periodic acid Schiff (AB-PAS) or
Elastica-Masson’s trichrome (EM). In order to esti-
mate the lung parenchymal inflammation quantita-
tively, cells that had accumulated in the parenchyma
were counted in 10 randomly selected fields of 500
μm squares in an H&E stained section using light mi-
croscopy. Quantification of alveolar enlargement was
determined by mean linear intercepts measured from
10 randomly selected lines passing through the lung
in the H&E stained sections. Changes in appearance
of the goblet cells were also quantitatively analyzed
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Fig. 3 The number of total cels, neutrophils and macrophages in the BALF was measured 24 hours af
ter the 15th exposure to LPS. Total cel counts and diferential cel counts (neutrophils) were caried out 
with light microscopy after staining with Trypan Blue and Dif Quick, respectively. Each column represents 
means ± S.E.M. (n＝4―6). Dex: Dexamethasone, Theo: Theophyline. #: p＜ 0.05, ##: p＜ 0.01 v.s. 
sham group.
0
1
2
3
4
1 3 30Sham Control
Dex Theo
##
0
5
10
15
1 3 30  (mg/kg)Sham Control
Dex Theo
##
(A) All cells (B) Neutrophils 
0
5
10
15
20
25
1 3 30  (mg/kg)Sham Control
Dex Theo
##
(C) Macrophages
(n ＝ 4―6)  
(n ＝ 4―6)  (n ＝ 4―6)  
C
el
l n
um
be
r 
(1
×
10
6 c
el
ls
)
C
el
l n
um
be
r 
(1
×
10
7 c
el
ls
)
C
el
l n
um
be
r 
(1
×
10
6 c
el
ls
)
with in AB-PAS-stained sections by light microscopy
and imaging software (Scion Image software, Scion
Corporation; National Institutes of Health, Frederick,
MD). The total area stained with AB-PAS at the air-
way surface was expressed in percentages of the in-
ternal area of the airway epithelium including airway
lumen.
MEASUREMENT OF AIRWAY HYPER-REACTI-
VITY
Airway hyper-reactivity was measured at 48 hours af-
ter the final exposure of LPS. Measurement of airway
hyper-reactivity was carried out using the Konzett-
Rössler method33 with some modification. In brief,
Guinea pigs were anesthetized with intraperitoneal
injection of 30 mgkg pentobarbital sodium, and
polyethylene catheters were inserted into the trachea
and jugular vein. After the arrest of spontaneous
breathing by intravenous injection of 5 mgkg succi-
nylcholine chloride, guinea pigs were ventilated us-
ing a respirator (model 7025, Ugo-basile Varese, It-
aly). The lung was inflated by a fixed volume of air
under 5 cm H2O pressure at a rate of 60 breaths
minute, and ventilation overflow was measured by a
differential pressure transducer (PUL123-DP45F,
M.I.P.S., Japan). Respiratory overflow was amplified
by bioelectric amplifier (AP-621 G, Nihon Kohden,
Tokyo, Japan) and recorded (WR 8500, Graphtec,
Yokohama, Japan). Escalating concentrations of
methacholine of 0, 1.875, 3.75, 7.5, 15, and 30 μgmL
kg were injected intravenously via a catheter in the
jugular vein, with dose intervals of 1 minute. Percent-
ages of bronchoconstriction after injection of meth-
acholine at each concentration were calculated from
the following formula: Percentage of bronchocon-
striction (%) = (Overflow after methacholine injection-
Overflow before methacholine injection)(Overflow
at complete occlusion-Overflow before methacholine
injection) × 100.
Airway hyper-reactivity of each group was ex-
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pressed as PC50, where the dose of methacholine
that induced 50% bronchoconstriction was calculated
from logarithmic regression of the dose-response
curves.
MEASUREMENT OF LUNG HYDROXYPROLINE
CONTENT
After measurement of AHR, the lung was removed
and weighed. Care was taken to remove adhered tis-
sue such as bronchia and vessels. The lungs were
then homogenized in 10 mL PBS. An aliquot of 0.5
mL of homogenate was hydrolyzed by 0.5 mL of 12N
HCl at 120℃ for 24 hours. After hydrolysis, 5 μL of
each sample was placed into a 96-well plate and
mixed with 5 μL citrateacetate solution (238 mM cit-
ric acid, 1.2% glacial acetic acid, 532 mM sodium ace-
tate, and 85 mM sodium hydroxide), and 100 μL of
chloramine-T solution (0.282 g chloramine-T added
to 16 mL citrateacetate solution, 2.0 ml of n-pro-
panol, and 2.0 mL distilled water) and incubated for
30 minutes at room temperature. Ehrlich’s reagent
(100 μL; 2.5 g p-dimethylaminobenzaldehyde added
to 9.3 mL of n-propanol and 3.9 mL of 70% perchloric
acid) was added, and incubated at 65℃ for 30 min-
utes. The absorbance of each sample was then meas-
ured at 550 nm with a microplate reader (Bio-Rad,
benchmark 170-6850, Tokyo, Japan).
STATISTICAL ANALYSIS
The data was represented as the mean ± S.E.M. Sta-
tistical significance was assessed by StatLight (Micro-
soft Windows 3.1 or 95Excel: Yukms Tokyo, Japan).
For comparison between the sham group and the
control group, the F-test and Student’s t-test or Wil-
coxon rank sum test were used. Multiple compari-
sons of the control group with the other treated
groups were evaluated by the Bartlett test, 1-way
ANOVA and Dunnett’s multiple test. A p-value of less
than 0.05 was considered to indicate a significant dif-
ference.
RESULTS
TIME COURSE OF CELL ACCUMULATION IN
BALF AND LUNG HYDROXYPROLINE CONTENT
We examined the changes in the number of BALF
cells and lung hydroxyproline content after the begin-
ning of LPS exposure. The number of total cells and
of neutrophils in BALF were found at maximum after
24 hours and 47 hours of 1st exposure of LPS
(Fig. 2A). Significant increases of the number of
BALF cells were also observed throughout the
course of this study, but repetition of LPS exposure
(5th, 10th and 15th exposure) did not induce any fur-
ther increase of the number of BALF cells. On the
other hand the lung hydroxyproline content in-
creased with repeated LPS exposures, and a signifi-
cant increase was found after the 15th exposure to
LPS (Fig. 2B). It was noted that lung weight was also
increased after the beginning of LPS exposure, with a
similar pattern of change to hydroxyproline content.
MEASUREMENT OF THE NUMBER OF LEUKO-
CYTES IN BRONCHOALVEOLAR LAVAGE
FLUID
The effects of either treatment with dexamethasone
or theophylline on the number of BALF cells are
shown in Figure 3. After the 15th exposure to LPS,
the total leukocyte count in BALF in the control
group was significantly increased (2.92 ± 0.35 × 107
cells, p < 0.01), compared with cells in the sham
group (0.66 ± 0.11 × 107 cells) (Fig. 3A). Differential
cell counts revealed that the number of neutrophils
was also significantly increased in the control group
(11.27 ± 1.49 × 106 cells, p < 0.01) compared with that
in the sham group (0.08 ± 0.01 × 106 cells) (Fig. 3B),
and the number of macrophages was also signifi-
cantly increased in the control group (15.89 ± 1.79 ×
106 cells, p < 0.01) compared with that in the sham
group (5.8 ± 0.91 × 106 cells) (Fig. 3C). However, the
number of eosinophils and lymphocytes did not
change significantly (data not shown). Dexametha-
sone or theophylline treatment did not effect any in-
crease in the total numbers of cells, neutrophils and
macrophages in BALF induced by LPS (Figs. 3A, 3B,
3C).
HISTOLOGICAL ANALYSIS
Accumulation of inflammatory cells on H&Estained
parenchyma of the lung after the 15th exposure to
LPS is shown in Figure 4. A large number of inflam-
matory cells such as macrophages and neutrophils
were found in the control group at higher magnifica-
tion (Fig. 8). In contrast, only a limited number of in-
flammatory cells could be found in the dexame-
thasone- and theophylline-treated groups. The aver-
age number of inflammatory cells in ten randomly
chosen fields (500 μm squares) counted with light
microscopy is shown in Figure 5A. The number of
cells counted in the control group was significantly in-
creased (47.1 ± 5.17 cellsfield, p < 0.01), compared
with the cells in the sham group (14.1 ± 0.60 cells
field). The increase in the number of cells induced
by LPS was significantly inhibited by theophylline (3
mgkg group, 34.7 ± 2.76 cellsfield; 30 mgkg
group, 23.1 ± 3.05 cellsfield; p < 0.01) or dexametha-
sone (29.1 ± 1.07 cellsfield; p < 0.05). Furthermore,
the mean linear intercept in the control group was
significantly increased (79.4 ± 7.99 μm, p < 0.01),
compared with the sham group (38.7 ± 2.25 μm). The
mean linear intercept of the theophylline-treated
group (3 mgkg group, 71.7 ± 9.20 μm, p = 0.54 and
30 mgkg group, 50.1 ± 5.48 μm; p < 0.05) was re-
duced significantly compared with that of the control
group. A reduced mean linear intercept was also
found in the dexamethasone-treated groups (62.4 ±
8.49 μm, p = 0.18), but this change was not signifi-
Kaneko Y et al.
450 Allergology International Vol 56, No4, 2007 www.jsaweb.jp
Fig. 4 Lung section stained with H&E at 24 hours after the 15th exposure to LPS. The 
photos show the sham group, the control group, the group treated with 1 mg/kg of dex
amethasone (Dex) and the group treated with 30 mg/kg of theophyline (Theo). 
Bar＝500 μm.
500 μm
Sham Control
Dex Theo
cant. Figure 6 shows large airway stained with AB-
PAS. The epithelial cells stained purple-magenta with
AB-PAS seemed to be typical goblet cells, and AB-
PAS-positive cells showed an increase in the control
group. These changes―such as goblet cell hyper-
plasia―were conspicuously reduced in the theophy-
lline-treated group and the dexamethasone-treated
group. Quantitative analysis of the AB-PAS stained
area is shown in Figure 7. The AB-PAS stained area
in the control group was significantly increased
(8.06 ± 2.17%, p < 0.05), compared with that in the
sham group (3.43 ± 0.94%). The AB-PAS stained area
of the theophylline-treated group (3 mgkg group;
2.34 ± 0.40%, 30 mgkg group; 1.86 ± 0.64%) was sig-
nificantly (p < 0.05) reduced from the corresponding
area in the control group. The AB-PAS stained area of
the dexamethasone-treated group (4.81 ± 0.83%) was
found to be reduced, but the difference in AB-PAS-
positive areas between the dexamethasone-treated
group and the control group was not significant. Swel-
ling of the alveolar wall, and increases of collagen,
elastic fiber and cell infiltration were found stained
with EM in the control group (Fig. 8). These changes
were less prominent in the dexamethasone-treated
group, and the theophylline-treated group showed an
almost normal structure similar to that found in the
sham group.
MEASUREMENT OF LUNG HYDROXYPROLINE
CONTENT
After the 15th exposure to LPS, lung collagen content
was measured quantitatively using hydroxyproline
analysis, and the results are shown in Figure 9A.
Lung hydroxyproline contents were 17.0 ± 2.88 mg
lung in the control group, 10.1 ± 1.36 mglung in the
sham group, 11.5 ± 1.21 mglung in the theophylline
treated group at a dose of 3 mgkg, 11.8 ± 1.11 mg
lung in the theophylline treated group at a dose of 30
mgkg, and 13.5 ± 2.11 mglung in the dexametha-
sone treated group, respectively. Lung hydroxy-
proline contents in the control group were signifi-
cantly increased (p < 0.05), compared with those in
the sham group. Lung hydroxyproline contents in the
theophylline treated group or dexamethasone treated
groups were found to be inhibited, but the differ-
ences in these groups were not significant. Lung
weight was also increased (control group; 4.07 ± 0.21
g, p < 0.05, v.s. sham group; 3.04 ± 0.10 g) after the
15th exposure to LPS, but this increase in lung weight
was not influenced by treatment with theophylline or
dexamethasone (Fig. 9B).
MEASUREMENT OF AIRWAY HYPER-REACTI-
VITY
Airway hyperreactivity was determined 48 hours after
the 15th exposure to LPS. Responses of each group to
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Fig. 5 Average number of inflammatory cels in ten randomly chosen fields (500 μm squares) and mean 
linear intercept measured from 10 randomly selected lines passing through the lung in the H&E stained 
sections. Each column represents means ± S.E.M. (n＝4―6). Dex: Dexamethasone, Theo: 
Theophyline. ##: p＜0.01 v.s. sham group, and ＊: p＜0.05, ＊＊: p＜0.01 v.s. control group.
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Fig. 6 Typical changes of airway epithelium stained with AB-PAS after the 15th exposure 
to LPS. The photos show the sham group, the control group, the group treated with 1 
mg/kg of dexamethasone (Dex) and the group treated with 30 mg/kg of theophyline 
(Theo). The epithelial cels which stained purple-magenta with AB-PAS were determined 
as goblet cels. Bar＝100 μm.
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the escalating dose of methacholine are shown in Fig-
ure 10A. The control group showed the most sensi-
tive response to methacholine among all groups stud-
ied. The airway hyper-reactivity of each group is ex-
pressed as PC50 (Fig. 10B). The PC50 value of the
control group was significantly decreased (2.57 ± 0.70
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Fig. 7 Goblet cel hyperplasia was quantitatively analysed 
and expressed as a percentage of the AB-PAS positive area 
at the airway lumen by image software. Each column repre-
sents means ± S.E.M. (n＝3―6). Dex: Dexamethasone, 
Theo: Theophyline. #: p＜ 0.05 v.s. sham group, and ＊ : 
p＜0.05 v.s. control group.
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μgkg, p < 0.01), compared with that of the sham
group (6.06 ± 1.08 gkg). The theophylline-treated
group at a dose of 30 mgkg showed the highest
PC50 value (9.73 ± 3.81 μgkg, p < 0.05). The PC50
value of the dexamethasone-treated group was also
high, but this change was not significant (8.36 ± 3.49
μgkg, p = 0.19).
DISCUSSION
In the present study, infiltration of inflammatory cells
in BALF was observed after first exposure to LPS,
and maintained at higher levels during repetitive ex-
posure to LPS. In contrast, lung hydroxyproline con-
tent increased with repetition of LPS exposures, and
significant increases were found after the 15th expo-
sure to LPS (Fig. 2). Repetitive exposure to LPS in-
duced several pathological changes such as inflam-
matory cell accumulation in the lung parenchyma, hy-
perplasia of goblet cells, hypersecretion of mucus, en-
largement of alveoli, swelling of the alveolar wall, and
increase of collagenic and elastic structures in the al-
veolus (Figs. 4, 6, 8). These pathological changes
were not evident until the 15th exposure to LPS (30
days after the start of the first exposure to LPS).
These results may suggest that chronic accumulation
of inflammatory cells was primarily induced by LPS,
and other pathological changes were induced secon-
darily. The pathological changes observed in this
study were consistent with those in previous re-
ports,9,10 and some of these changes have been
known in human lung injury such as COPD32 and
ARDS.23
The accumulation of inflammatory cells in the lung
parenchyma after the 15th exposure to LPS was inhib-
ited by treatment with either theophylline or dex-
amethasone, but the increased number of inflamma-
tory cells in the BALF was not changed by either
treatment. This discrepancy might be explained in
part by the different strength of LPS exposure, i.e.
the proximal bronchus was exposed to too much LPS
to prove the response to drugs used, and the lung pa-
renchyma was exposed to the minimal quantity of
LPS that could cause pathological changes observed
by the present study condition of LPS at 30 μgmL.
As shown in Figures 4, 8, inflammatory cell accumu-
lation in the alveolus was clearly inhibited by the
treatment of both theophylline and dexamethasone,
and such anti-inflammatory effects of both drugs in
the lung parenchyma may contribute to reduce fur-
ther destruction of the lung and airway epithelium.
Anti-inflammatory effects of dexamethasone on
LPS-induced cell accumulation in the BALF could not
be found in the present study. However, some re-
ports showed inhibition of cell infiltration in the
BALF after LPS exposure. Toward et al. reported that
dexamethasone reduced neutrophil influx at a dose of
20 mgkg p.o. in a guinea pig model of pulmonary
edema induced by chronic LPS exposure.10 Another
report showed inhibition of neutrophilia in guinea
pigs after single exposure to LPS with treatment of 5
mgkg dexamethasone.34 Thus it might be suggested
that larger doses of dexamethasone would be re-
quired in the present study to inhibit cell infiltration
in the BALF. On the other hand, the effect of theo-
phylline on LPS-induced cell accumulation in the
BALF has been examined, and theophylline at a dose
of 50 mgkg p.o. could not inhibit inflammatory cell
influx in the BALF of guinea pig35 and rat36 models of
pulmonary edema induced by single LPS exposure.
Escofier et al. reported that theophylline at a dose of
100 mgkg inhibited neutrophilia induced by single
exposure to LPS in rats,37 but a dose of 100 mgkg
theophylline seemed to be inadequate for repeated
administration because of severe adverse effects.
These reports suggest that the anti-inflammatory ef-
fect of theophylline might not be sufficient for pre-
venting inflammatory cell influx in the BALF,
whereas theophylline showed improvement of inflam-
matory cell accumulation in the lung parenchyma.
Hypersecretion of mucus and hyperplasia of goblet
cells in the airway is recognized as an important
cause of airflow limitation in patients with COPD.
Similar histological changes of the airway have been
observed in some animal models including LPS expo-
sure.9,38 Hyperplasia of goblet cells was also found in
the present study (Fig. 6), and such change induced
by repetitive exposure to LPS was prevented by treat-
ment with either theophylline or dexamethasone.
One report using chronic LPS exposure showed that
dexamethasone and rolipram, a selective inhibitor of
PDE IV, inhibited the increase of goblet cells in the
airway of guinea pigs dose dependently.9 The protec-
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Fig. 8 Representative sections of the lung were stained with EM after the 15th exposure 
to LPS. The photos show the sham group, the control group, the group treated with 1 
mg/kg of dexamethasone (Dex) and the group treated with 30 mg/kg of theophyline 
(Theo). The alveolar wals which stained green-blue and dark blue with EM were found to 
be colagenic fibers and elastic fibers, respectively. The inflammatory cels in the alveolar 
sections are indicated by gray arows (macrophages) and white arows (neutrophils). 
Bar＝100 μm.
100 μm
Sham Control
Dex Theo
Fig. 9 After the 15th exposure to LPS, lung colagen content was measured quantitatively using hydroxy
proline analysis. Lung weight (A) and hydroxyproline content (B) were measured 48 hours after the 15th 
exposure to LPS. The lungs were removed and weighed, then hydroxyproline of the lung was measured 
using Ehrlich’ sreagent. Each column represents means ± S.E.M. (n＝4―6). Dex: Dexamethasone, 
Theo: Theophyline. #: p＜0.05, ##: p＜0.01 v.s. sham group.
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Fig. 10 Airway hypereactivity was examined after the 15th exposure to LPS with increasing concentra-
tion of methacholine (A). Airway response to intravenous injection of methacholine was expressed as rela-
tive bronchoconstriction where mechanical occlusion of tracheal cannula was determined as 100%. Each 
point represents means ± S.E.M. (n＝4―6). Dex; Dexamethasone, Theo; Theophyline. #: p＜0.05 v.s. 
sham group, and ＊: p＜0.05 v.s. control group. (B) Airway hyper-reactivity of each group was expressed 
as PC50, indicating the methacholine dose (mg/kg) at which 50% bronchoconstriction was induced. Each 
column shows means ± S.E.M. (n＝4―6). Dex: Dexamethasone, Theo: Theophyline. ##: p＜ 0.01 
v.s. sham group, and ＊＊: p＜0.01 v.s. control group.
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tive effects on goblet cell hyperplasia induced by
OVA were also reported; for example, Kumar et al. re-
ported ameliorative effects of roflumilast, a selective
PDE IV inhibitor, on goblet cell hyperplasia using a
remodeling model of mice induced by OVA.39 Fur-
thermore, Sun et al. reported a positive relation be-
tween the extent of goblet cell hyperplasia and in-
crease of cAMP-PDE activity.40 In consideration of
the results of these reports, the ameliorative effects of
theophylline on goblet cell hyperplasia were depend-
ent on its inhibition of cAMP-PDE.
Swelling and destruction of the alveolar wall are
considered to be other causes of symptoms in COPD
patients. Irreversible destruction of the alveolar wall
and airspace enlargement lead to decreased lung
elastic recoil, and then cause airflow limitation and
dynamic airway compression.28 In the present study,
enlargement of alveoli and swelling of the alveolar
wall was noted after the 15th exposure to LPS (Figs.
5B, 8). These pathological changes might be related
to the increase in lung hydroxyproline content during
the course of this experiment(Fig. 9), suggesting fi-
brotic aspects of the pathophysiology of this guinea
pig model induced by the present experimental con-
dition. Theophylline improved such pathological
changes, but the mechanisms of action were not obvi-
ous. In the previous report using a chronic LPS expo-
sure model in mice, swelling of the alveolar wall was
observed together with large increases in transform-
ing growth factor (TGF)-β1 concentration in BALF
and Penh, an index of airflow limitation.7 TGF-β has
been recognized as the most important factor of fi-
brotic disease such as emphysema, pulmonary fibro-
sis and airway remodeling. Recent reports have
shown that induction of COL1 (type I collagen)
mRNA and α-smooth muscle actin protein by TGF-β
stimulus is inhibited by theophylline in in vitro ex-
periments with lung fibroblast.41 Taking these re-
ports into account, it may be suggested that the ob-
served effects of theophylline on improvement of
swelling of the alveolar wall and increases in lung hy-
droxyproline content appeared via inhibition of the
signal transduction system of TGF-β.
At last, AHR was examined as a functional end-
point, and it was found that higher doses of theophyl-
line inhibited the airway response to methacholine
(Fig. 10). Uno et al. reported that theophylline (50
mgkg) could inhibit acetylcholine induced AHR
without inhibiting influx of inflammatory cells in the
BALF,35 and our results were found to be consistent
with this report. The effects of theophylline on airway
disease are usually believed to depend on its anti-
inflammatory action and bronchodilatory action. Im-
proved airway hyperreactivity observed in the
theophylline-treated group in the present study, how-
ever, depends mainly on its anti-inflammatory actions
because airway hyperreactivity was measured at 48
hours after final administration of theophylline.
Anti-inflammatory effects of theophylline might
play important roles for the prevention of lung de-
Theophylline Improves Chronic Lung Injury
Allergology International Vol 56, No4, 2007 www.jsaweb.jp 455
struction and goblet cell hyperplasia, and airway reac-
tivity might be maintained at normal levels with pre-
served lung structure. Furthermore, the anti-infla-
mmatory effects of theophylline might depend on its
inhibition of PDE. In addition, other mechanisms of
action including adenosine receptor antagonism,43 in-
hibition interleukin release (IL-1β, IL-4 and IL-5),30,44
increased IL-10 release,44 mediator inhibition (leukot-
riene (LT) B4, LTC4, prostaglandins, TNF-α),42,44 in-
hibition of intracellular calcium release,45 inhibition
of NF-kappa B,46 and increased histone deacetylase
activity31 have been proposed for the clinical effects
of theophylline. These mechanisms of action might
contribute to the ameliorative effects of theophylline
observed in the present study.
In summary, theophylline improved some aspects
of the pathological changes induced by repetitive ex-
posure to LPS. These include accumulation of inflam-
matory cells in the lung parenchyma, hyperplasia of
goblet cells, and swelling of the alveolar wall. Airway
hyperreactivity was also improved by treatment with
theophylline. These effects of theophylline observed
in the present study may contribute to improvement
of some symptoms, pathological changes as well as
airflow limitations in patients with chronic airway dis-
ease.
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